Oruka Therapeutics, Inc. ORKA Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months)?
- Oruka Therapeutics, Inc. (ORKA) reported available-for-sale debt securities - unrealized loss position (<12 months) of $348.72M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months) changed year-over-year?
- Oruka Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months) increased by 58.6% year-over-year, from $219.8M to $348.72M.
- What does available-for-sale debt securities - unrealized loss position (<12 months) mean?
- This metric identifies debt securities classified as available-for-sale that have been in an unrealized loss position for a period of less than one year. It helps investors distinguish between temporary market fluctuations and potential long-term credit impairment issues.